Management of hypertensive crises: The scientific basis for treatment decisions

被引:61
作者
Blumenfeld, JD
Laragh, JH
机构
[1] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Cardiothorac Surg, New York, NY USA
[2] Rogosin Inst, New York, NY 10021 USA
关键词
D O I
10.1016/S0895-7061(01)02245-2
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The spectrum of disorders associated with an elevated blood pressure (BP) encompasses chronic uncomplicated hypertension and the hypertensive crises, including hypertensive urgencies and emergencies. Although these syndromes vary widely in their presentations, clinical courses, and outcomes they share pathophysiologic mechanisms and, consequently, therapeutic responses to specifically targeted antihypertensive drug types. Nevertheless, hypertensive crises are often treated with drugs which, in that setting are either unsafe or are of unsubstantiated efficacy. The purpose of this review is to examine the pathophysiology of commonly encountered hypertensive crises, including stroke, hypertensive encephalopathy, aortic dissection, acute pulmonary edema, and preeclampsiaeclampsia and to provide a rational approach, to their treatment based upon relevant pathophysiologic and pharmacologic principles. Measurement of plasma renin activity (PRA) level often provides insight regarding pathophysiology and predicts efficacy of antihypertensive treatments in the individual patient. However, in hypertensive crises, drug therapy is initiated before the PRA level is known. Nevertheless, the renin-angiotensin dependence (R-type) or volume dependence (V-type) of hypertension can often be deduced by the BP response to drugs that interrupt the renin system (R-drugs) or that decrease body volume (V-drugs). Based upon these considerations, a treatment algorithm is provided to guide drug selection in patients presenting with a hypertensive crisis. Am J Hypertens 200 1; 14:1154-1167 (C) 2001 American Journal of Hypertension, Ltd.
引用
收藏
页码:1154 / 1167
页数:14
相关论文
共 81 条
[71]   Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study [J].
Vantrimpont, P ;
Rouleau, JL ;
Ciampi, A ;
Harel, F ;
de Champlain, J ;
Bichet, D ;
Moye, LA ;
Pfeffer, M .
EUROPEAN HEART JOURNAL, 1998, 19 (10) :1552-1563
[72]   SPIRONOLACTONE IN CONGESTIVE-HEART-FAILURE REFRACTORY TO HIGH-DOSE LOOP DIURETIC AND LOW-DOSE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR [J].
VANVLIET, AA ;
DONKER, AJM ;
NAUTA, JJP ;
VERHEUGT, FWA .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (03) :A21-A28
[73]   Hypertensive emergencies [J].
Vaughan, CJ ;
Delanty, N .
LANCET, 2000, 356 (9227) :411-417
[74]  
VIDT D, 2001, J CLIN HYPERTENS, V111, P158
[75]   BLOOD-PRESSURE AFTER STROKE [J].
WALLACE, JD ;
LEVY, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 246 (19) :2177-2180
[76]   NITROPRUSSIDE IN PREECLAMPSIA - CIRCULATORY DISTRESS AND PARADOXICAL BRADYCARDIA [J].
WASSERSTRUM, N .
HYPERTENSION, 1991, 18 (01) :79-84
[77]   TREATMENT OF DISSECTING ANEURYSMS OF AORTA WITHOUT SURGERY [J].
WHEAT, MW ;
PALMER, RF ;
BARTLEY, TD ;
SEELMAN, RC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1965, 50 (03) :364-&
[78]   CONTROL OF HYPERTENSION WITH NIFEDIPINE IN THE SETTING OF AORTIC DISSECTION [J].
WHITE, SR ;
HALL, JB .
CHEST, 1985, 88 (05) :780-781
[79]   Magnesium sulfate therapy in preeclampsia and eclampsia [J].
Witlin, AG ;
Sibai, BM .
OBSTETRICS AND GYNECOLOGY, 1998, 92 (05) :883-889
[80]   CAPTOPRIL REDUCES THE DOSE REQUIREMENT FOR SODIUM-NITROPRUSSIDE INDUCED HYPOTENSION [J].
WOODSIDE, J ;
GARNER, L ;
BEDFORD, RF ;
SUSSMAN, MD ;
MILLER, ED ;
LONGNECKER, DE ;
EPSTEIN, RM .
ANESTHESIOLOGY, 1984, 60 (05) :413-417